Caris Life Sciences Partners with Beat Childhood Cancer Research Consortium at Penn State University to Improve Outcomes for Pediatric Patients
IRVING, Texas, March 5, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced an ongoing collaboration with the Beat Childhood Cancer Research Consortium, a group of over 50 universities and children's hospitals, based at Penn State College of Medicine in Hershey, Pa., that offers a worldwide network of pediatric cancer clinical trials.
- Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
- As part of the collaboration to advance precision oncology and biomarker-driven research, Caris is now the molecular analysis partner for Beat Childhood Cancer Research Consortium studies.
- In addition to tumor sequencing for new or recurring pediatric cancer patients, Caris and the Beat Childhood Cancer Research Consortium will also collaborate on research opportunities striving to advance pediatric patient care and improve outcomes.
- "The Beat Childhood Cancer Research Consortium is excited to collaborate with Caris to expand our precision medicine program.